Spots Global Cancer Trial Database for Namodenoson Treatment of Advanced Pancreatic Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Namodenoson Treatment of Advanced Pancreatic Cancer
Official Title: CF102-222PC: A Phase 2 Open-Label Study of the Safety and Activity of Namodenoson in the Treatment of Advanced Pancreatic Adenocarcinoma
Study ID: NCT06387342
Interventions
Study Description
Brief Summary: This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients.
Detailed Description: All patients will receive the study drug twice daily. The study drug is given as a capsule, orally (by mouth). Patients will be monitored regularly for safety. Tumor imaging will be performed approximately every two months. Patients can decide to stop the treatment with study drug at any time.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rabin Medical Center Institute of Oncology, Petach Tikva, , Israel
Contact Details
Name: Michael H Silverman, MD
Affiliation: Can-Fite BioPharma
Role: STUDY_DIRECTOR
Name: Salomon M Stemmer, MD
Affiliation: Rabin Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
